Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMALYST vs ADDERALL 12.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Multiple myeloma (in combination with dexamethasone) in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy,AIDS-related Kaposi sarcoma (in patients with AIDS-related Kaposi sarcoma who have failed highly active antiretroviral therapy [HAART] or are intolerant to HAART)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy (off-label)
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Pomalidomide is primarily metabolized by cytochrome P450 (CYP) 1A2 and CYP3A4. It also undergoes hydroxylation and subsequent glucuronidation. Minor pathways include CYP2C19 and CYP2D6.
Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine.
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is p H-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
33% bound to human plasma proteins, predominantly to albumin.
Approximately 15–20% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is approximately 120 L (1.7 L/kg for a 70 kg individual), indicating extensive tissue distribution beyond plasma volume.
Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence.
Oral bioavailability is approximately 73% (range: 66-81%). Administration with a high-fat meal decreases Cmax by 36% and AUC by 26% relative to fasting; therefore, take on an empty stomach.
Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release.
For Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: reduce dose to 3 mg once daily; Cr Cl <30 m L/min: not recommended (no dose established).
GFR 15-29 m L/min: reduce dose to 50% of usual; GFR <15 m L/min: use 50% of usual dose; hemodialysis: not removed, avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 3 mg once daily; Child-Pugh C: reduce dose to 2 mg once daily.
Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use.
Safety and efficacy not established in pediatric patients; no standard dosing.
Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
No specific dose adjustment based on age alone; monitor for toxicity and adjust based on renal function as per adult recommendations.
Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation.
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM. Pomalidomide is contraindicated in pregnant women because it can cause severe birth defects or death to an unborn baby. Females of reproductive potential must avoid pregnancy during treatment and for at least 4 weeks after the last dose. Pomalidomide is only available through a restricted distribution program called the POMALYST REMS program. Additionally, pomalidomide significantly increases the risk of venous and arterial thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke). Thromboprophylaxis is recommended.
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Embryo-fetal toxicity: Can cause fetal harm; females of reproductive potential must use effective contraception and avoid pregnancy. Males should avoid donating sperm.,Thromboembolism: Increased risk of venous and arterial thromboembolic events; thromboprophylaxis recommended.,Hematologic toxicity: Neutropenia and thrombocytopenia are common; monitor blood counts regularly.,Hepatotoxicity: Can cause elevated liver enzymes and hepatic failure; monitor liver function tests.,Cardiac toxicity: Increased risk of heart failure, myocardial infarction, and atrial fibrillation.,Hypersensitivity reactions: Including angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis; discontinue if severe reaction occurs.,Tumor lysis syndrome: Monitor patients at risk.,Interference with oral contraceptives: May reduce efficacy of oral contraceptives; consider additional non-hormonal contraception.
Risk of abuse and dependence,Serious cardiovascular events including sudden death, stroke, and myocardial infarction,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with seizure disorders,Visual disturbances,Growth suppression in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when used with serotonergic drugs
Pregnancy,Hypersensitivity to pomalidomide or any component of the formulation
Known hypersensitivity to amphetamine products or other sympathomimetic amines,Concomitant use with MAOIs or within 14 days of MAOI therapy,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction. No specific dietary restrictions otherwise; take with or without food. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid alcohol due to increased risk of liver toxicity.
Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels.
Pomalidomide is an immunomodulatory drug (IMi D) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth defects or embryo-fetal death. Fetal exposure during any trimester can cause major congenital malformations, including limb defects, craniofacial anomalies, and cardiovascular abnormalities. Use in females of reproductive potential requires negative pregnancy testing before treatment, and use of two effective contraceptive methods during therapy and for 4 weeks after discontinuation. Pregnancy testing frequency: weekly during first month, then every 2-4 weeks if regular cycles, or every 2 weeks if irregular cycles.
First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported.
It is unknown whether pomalidomide is excreted in human milk. Due to the potential for serious adverse reactions in breastfeeding infants, women should not breastfeed during treatment with pomalidomide. No M/P ratio is available.
Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain.
Pomalidomide is contraindicated in pregnancy; no dose adjustments are applicable because use during pregnancy is not recommended. If exposure occurs, the manufacturer recommends immediate discontinuation and referral to a teratology specialist. No pharmacokinetic studies on pregnancy-related dose adjustments exist.
Pharmacokinetics altered: increased hepatic metabolism and renal clearance in pregnancy may reduce amphetamine exposure; however, safety data do not support dose adjustment. Use lowest effective dose only if necessary; consider alternative non-amphetamine therapies.
Pomalidomide is an immunomodulatory drug used in multiple myeloma after prior therapies including lenalidomide and bortezomib. Requires baseline and periodic CBCs, liver and renal function tests. High risk for venous thromboembolism; prophylaxis with aspirin or anticoagulation recommended. Contraindicated in pregnancy due to severe teratogenicity, necessitating REMS program. Dose adjust for renal impairment (Cr Cl <45 m L/min) and hepatic impairment (Child-Pugh C). Monitor for tumor lysis syndrome, especially in patients with high tumor burden.
ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules.
Pomalidomide is a chemotherapy drug that helps treat multiple myeloma by targeting cancer cells.,Do not take if pregnant or planning to become pregnant; use effective contraception during treatment and for 4 weeks after stopping.,Do not breastfeed while taking pomalidomide.,Report any signs of bleeding, bruising, fever, shortness of breath, or chest pain immediately.,Take exactly as prescribed; do not break, chew, or crush capsules; swallow whole with water.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Avoid live vaccines while on this medication.,Store at room temperature away from moisture and heat.,Keep all appointments for blood tests and other monitoring.,Inform all healthcare providers that you are taking pomalidomide.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow the capsule whole; do not chew, crush, or open it.,Avoid alcohol while taking this medication.,Do not drive or operate machinery until you know how this medication affects you.,Report any chest pain, shortness of breath, or fainting to your doctor immediately.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMALYST vs ADDERALL 12.5, answered by our medical review team.
POMALYST is a Immunomodulatory Agent that works by Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b FGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.. ADDERALL 12.5 is a CNS Stimulant that works by Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMALYST and ADDERALL 12.5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMALYST is: 4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.. The standard adult dose of ADDERALL 12.5 is: 5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMALYST and ADDERALL 12.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMALYST is classified as Category C. Pomalidomide is an immunomodulatory drug (IMiD) structurally related to thalidomide, a known human teratogen. It is contraindicated in pregnancy due to high risk of severe birth de. ADDERALL 12.5 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.